

# Jeremy S Abramson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1661555/publications.pdf>

Version: 2024-02-01

195  
papers

7,627  
citations

71102

41  
h-index

58581

82  
g-index

196  
all docs

196  
docs citations

196  
times ranked

7934  
citing authors

#	ARTICLE	IF	CITATIONS
1	Engineered T Cells: CAR T Cell Therapy and Beyond. <i>Current Oncology Reports</i> , 2022, 24, 23-31.	4.0	23
2	Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study. <i>Blood Advances</i> , 2022, , .	5.2	14
3	Case 14-2022: A 57-Year-Old Man with Chylous Ascites. <i>New England Journal of Medicine</i> , 2022, 386, 1834-1844.	27.0	0
4	First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7503-7503.	1.6	9
5	NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 622-634.	4.9	33
6	Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma. <i>Blood</i> , 2022, 140, 1822-1826.	1.4	8
7	A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma. <i>Cancer Research Communications</i> , 2022, 2, 795-805.	1.7	11
8	Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. <i>Blood</i> , 2021, 137, 1353-1364.	1.4	31
9	Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study. <i>Hematological Oncology</i> , 2021, 39, 185-195.	1.7	12
10	Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial. <i>Blood Advances</i> , 2021, 5, 1695-1705.	5.2	18
11	CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (cHL).. <i>Journal of Clinical Oncology</i> , 2021, 39, 7507-7507.	1.6	7
12	First-in-human data of ALLO-501A, an allogeneic chimeric antigen receptor (CAR) T-cell therapy and ALLO-647 in relapsed/refractory large B-cell lymphoma (R/R LBCL): ALPHA2 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2529-2529.	1.6	18
13	Impact of initial biopsy type on the time to final diagnostic biopsy in patients with follicular lymphoma and suspected histologic transformation. <i>Leukemia and Lymphoma</i> , 2021, 62, 2864-2872.	1.3	4
14	Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. <i>Leukemia</i> , 2021, 35, 2854-2861.	7.2	12
15	Efficacy and safety of CD19-directed CAR cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials. <i>American Journal of Hematology</i> , 2021, 96, 1295-1312.	4.1	107
16	Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.4	1
17	Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study. <i>Lancet Haematology</i> , 2021, 8, e818-e827.	4.6	14
18	Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.4	1

#	ARTICLE	IF	CITATIONS
19	Accuracy of Pathologic Diagnosis in Patients With Lymphoma and Survival: A Prospective Analysis From Botswana. <i>JCO Global Oncology</i> , 2021, 7, 1620-1632.	1.8	0
20	Complete Remission with Devimistat (CPI-613) in Refractory Burkitt Lymphoma. <i>Blood</i> , 2021, 138, 4555-4555.	1.4	2
21	Safety and Efficacy of Ibrutinib Maintenance (I-M) Following Frontline Induction in Mantle Cell Lymphoma (MCL) with Sequential Assessment of Changes in NGS-MRD. <i>Blood</i> , 2021, 138, 3530-3530.	1.4	0
22	ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing. <i>Blood</i> , 2021, 138, 649-649.	1.4	22
23	NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1218-1230.	4.9	98
24	PK and PD Assessment of BET Inhibitor Pelabresib (CPI-0610) in Patients with Relapsed or Refractory Lymphoma: Findings from a Phase 1 Study. <i>Blood</i> , 2021, 138, 1202-1202.	1.4	3
25	Zanubrutinib, Obinutuzumab, and Venetoclax in Chronic Lymphocytic Leukemia: Early MRD Kinetics Define a High-Risk Patient Cohort with Delayed Bone Marrow Undetectable MRD and Earlier Post-Treatment MRD Recurrence. <i>Blood</i> , 2021, 138, 3753-3753.	1.4	1
26	Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL). <i>Blood</i> , 2021, 138, 2840-2840.	1.4	34
27	Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Compared with Standard of Care (SOC) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study. <i>Blood</i> , 2021, 138, 3845-3845.	1.4	9
28	Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2021, 138, 640-640.	1.4	4
29	Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy. <i>Blood</i> , 2021, 138, 639-639.	1.4	27
30	Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701. <i>Blood</i> , 2021, 138, 523-523.	1.4	14
31	Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study. <i>Blood</i> , 2021, 138, 81-81.	1.4	70
32	Prognostic Factors Other Than Age Drive the Risk of Disease Progression in Adults with Burkitt Lymphoma Treated with DA-EPOCH-R. <i>Blood</i> , 2021, 138, 453-453.	1.4	0
33	Novel Genetic Subgroups Inform on Shared Pathobiology within Adult and Pediatric Burkitt Lymphoma. <i>Blood</i> , 2021, 138, 806-806.	1.4	4
34	Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e879-e890.	4.6	48
35	Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma. <i>Transfusion Medicine Reviews</i> , 2020, 34, 29-33.	2.0	81
36	Modern management of relapsed and refractory aggressive B-cell lymphoma: A perspective on the current treatment landscape and patient selection for CAR T-cell therapy. <i>Blood Reviews</i> , 2020, 40, 100640.	5.7	32

#	ARTICLE	IF	CITATIONS
37	Non-Hodgkin Lymphomas. , 2020, , 1926-1947.e5.		0
38	Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. Journal of Clinical Oncology, 2020, 38, 3095-3106.	1.6	216
39	Evaluation of the impact of timing of pegfilgrastim administration on incidence of febrile neutropenia in elderly patients with B-cell non-Hodgkin lymphomas receiving R-CHOP-21. Leukemia and Lymphoma, 2020, 61, 2998-3001.	1.3	1
40	A virtual resiliency program for lymphoma survivors: helping survivors cope with post-treatment challenges. Psychology and Health, 2020, 36, 1-16.	2.2	10
41	Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet, The, 2020, 396, 839-852.	13.7	1,224
42	ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 302-313.	3.8	19
43	Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. Journal of Clinical Oncology, 2020, 38, 2519-2529.	1.6	93
44	Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomas. Leukemia and Lymphoma, 2020, 61, 2561-2567.	1.3	16
45	Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001. Blood, 2020, 136, 10-11.	1.4	52
46	Phase I study of the Bcl-2 inhibitor venetoclax with DA-EPOCH-R as initial therapy for aggressive B-cell lymphomas.. Journal of Clinical Oncology, 2020, 38, 8003-8003.	1.6	4
47	Initial results of a multicenter, investigator initiated study of MRD driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax.. Journal of Clinical Oncology, 2020, 38, 8006-8006.	1.6	15
48	Outpatient treatment with lisocabtagene maraleucel (liso-cel) across a variety of clinical sites from three ongoing clinical studies in relapsed/refractory (R/R) large B-cell lymphoma (LBCL).. Journal of Clinical Oncology, 2020, 38, 8037-8037.	1.6	12
49	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 185-217.	4.9	40
50	Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202.. Journal of Clinical Oncology, 2020, 38, e20004-e20004.	1.6	0
51	Characterization of cytokine release syndrome (CRS) and neurological events (NEs) in the phase I TRANSCEND NHL 001 trial of lisocabtagene maraleucel (liso-cel) for patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).. Journal of Clinical Oncology, 2020, 38, e20046-e20046.	1.6	0
52	Results of a completed phase I study of LAM-002 (apilimod dimesylate), a first-in-class phosphatidylinositol-3-phosphate 5 kinase (PIKfyve) inhibitor, administered as monotherapy or with rituximab or atezolizumab to patients with previously treated follicular lymphoma or other B-cell cancers.. Journal of Clinical Oncology, 2020, 38, 8017-8017.	1.6	3
53	Management of BTK Inhibitor Associated Adverse Events: Current Practice Trends Among Healthcare Providers and Concordance with Expert Recommendations. Blood, 2020, 136, 5-6.	1.4	0
54	Ibrutinib Maintenance (I-M) Following Intensive Induction in Mantle Cell Lymphoma (MCL): Efficacy, Safety and Changes in Minimal Residual Disease. Blood, 2020, 136, 30-31.	1.4	1

#	ARTICLE	IF	CITATIONS
55	Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. <i>Lancet Haematology</i> , 2019, 6, e419-e428.	4.6	60
56	Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?. <i>Cancer</i> , 2019, 125, 3111-3120.	4.1	17
57	Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. <i>Blood</i> , 2019, 134, 860-866.	1.4	178
58	Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma. <i>Cancer</i> , 2019, 125, 3692-3698.	4.1	42
59	Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma. <i>Blood</i> , 2019, 134, 606-613.	1.4	41
60	Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 446-453.	3.8	20
61	Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 2931-2938.	1.3	4
62	Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. <i>Journal of Clinical Oncology</i> , 2019, 37, 1790-1799.	1.6	266
63	Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. <i>Blood</i> , 2019, 133, 2212-2221.	1.4	207
64	Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. <i>Blood Advances</i> , 2019, 3, 1167-1174.	5.2	23
65	Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T). <i>Journal of the American College of Cardiology</i> , 2019, 74, 3099-3108.	2.8	225
66	Advances in risk assessment and prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2019, 104, 25-34.	3.5	37
67	Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. <i>Blood</i> , 2019, 133, 1313-1324.	1.4	172
68	High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR). <i>Blood</i> , 2019, 134, 4291-4291.	1.4	1
69	Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation. <i>Blood</i> , 2019, 134, 3990-3990.	1.4	1
70	Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas. <i>Blood</i> , 2019, 134, 241-241.	1.4	89
71	Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT. <i>Blood</i> , 2019, 134, 2868-2868.	1.4	13
72	A Phase II Clinical Trial of Cpi-613 (devimstat) in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma with Rearrangements of MYC and BCL2 and/or BCL6. <i>Blood</i> , 2019, 134, 4087-4087.	1.4	4

#	ARTICLE	IF	CITATIONS
73	Burden of cytokine release syndrome (CRS) and neurologic events (NE) in patients (Pts) with relapsed/refractory non-Hodgkin lymphoma (NHL) receiving lisocabtagene maraleucel (Liso-cel); Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.4	10
74	NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 650-661.	4.9	116
75	Impact of HIV Infection on the Clinical Presentation and Survival of Non-Hodgkin Lymphoma: A Prospective Observational Study From Botswana. Journal of Global Oncology, 2018, 4, 1-11.	0.5	14
76	Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 prospective, multicentre, single-arm phase 2 study. Lancet Haematology,the, 2018, 5, e609-e617.	4.6	152
77	Human Herpes Virus 8 in HIV-1 infected individuals receiving cancer chemotherapy and stem cell transplantation. PLoS ONE, 2018, 13, e0197298.	2.5	6
78	Panobinostat in combination with rituximab in heavily pretreated diffuse large Bâ€cell lymphoma: Results of a phase II study. Hematological Oncology, 2018, 36, 633-637.	1.7	14
79	EEG findings in CAR T-cell therapy-related encephalopathy. Neurology, 2018, 91, 227-229.	1.1	37
80	Design and clinical validation of a point-of-care device for the diagnosis of lymphoma via contrast-enhanced microholography and machine learning. Nature Biomedical Engineering, 2018, 2, 666-674.	22.5	55
81	Estimation of the Resource Utilization and Costs of Cytokine Release Syndrome Observed in the Transcend-NHL Clinical Trial: A Micro-Costing Study. Blood, 2018, 132, 319-319.	1.4	5
82	A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma. Blood, 2018, 132, 1654-1654.	1.4	2
83	Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202. Blood, 2018, 132, 6-6.	1.4	18
84	Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity. Blood, 2018, 132, 92-92.	1.4	74
85	Procalcitonin As a Potential Biomarker for Differentiating Bacterial Infectious Fevers from Cytokine Release Syndrome. Blood, 2018, 132, 4216-4216.	1.4	5
86	Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.. Journal of Clinical Oncology, 2018, 36, 7505-7505.	1.6	130
87	High durable CR rates and preliminary safety profile for JCAR017 in R/R aggressive b-NHL (TRANSCEND) Tj ETQq1 1 0.784314 rgBT /Over administration.. Journal of Clinical Oncology, 2018, 36, 120-120.	1.6	23
88	Correlation of patient characteristics and biomarkers with clinical outcomes of JCAR017 in R/R aggressive B-NHL (TRANSCEND NHL 001 study).. Journal of Clinical Oncology, 2018, 36, 122-122.	1.6	9
89	Abstract 3674: Pharmacodynamic assessment in whole blood for the BET bromodomain inhibitor CPI-0610 of target engagement in patients with progressive lymphoma. , 2018, , .		1
90	Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation. Leukemia and Lymphoma, 2017, 58, 222-225.	1.3	6



#	ARTICLE	IF	CITATIONS
91	Case 5-2017. <i>New England Journal of Medicine</i> , 2017, 376, 684-692.	27.0	11
92	Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy. <i>Journal of Infectious Diseases</i> , 2017, 216, 254-262.	4.0	41
93	NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 293-311.	4.9	55
94	Recurrent mutations and targeted therapy in FL. <i>Blood</i> , 2017, 129, 402-403.	1.4	0
95	The landscape of new drugs in lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 335-346.	27.6	56
96	Treatment of Relapsed DLBCL. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S165.	0.4	0
97	Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 783-784.	27.0	170
98	More on Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 2101-2102.	27.0	16
99	Imaging for Oncologic Response Assessment in Lymphoma. <i>American Journal of Roentgenology</i> , 2017, 208, 18-31.	2.2	22
100	Bone marrow biopsies for staging of diffuse large B-cell lymphoma: are we looking too closely?. <i>Leukemia and Lymphoma</i> , 2017, 58, 4-5.	1.3	2
101	Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. <i>Blood Advances</i> , 2017, 1, 2600-2609.	5.2	62
102	ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-Cell Receptors (ACTR), Induces Complete Responses in Patients with Relapsed or Refractory CD20-Positive B-Cell Lymphoma, in Combination with Rituximab. <i>Blood</i> , 2017, 130, 580-580.	1.4	2
103	CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017 (TRANSCEND NHL 001).. <i>Journal of Clinical Oncology</i> , 2017, 35, 7513-7513.	1.6	24
104	Holographic Assessment of Lymphoma Tissue (HALT) for Global Oncology Field Applications. <i>Theranostics</i> , 2016, 6, 1603-1610.	10.0	12
105	Small-cell predominant extranodal <sc>NK</sc>/T cell lymphoma, nasal type: clinicopathological analysis of a series of cases diagnosed in a Western population. <i>Histopathology</i> , 2016, 69, 667-679.	2.9	20
106	Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma. <i>Cancer</i> , 2016, 122, 559-564.	4.1	67
107	Chemotherapy-sparing treatment strategies for follicular lymphoma. <i>Current Opinion in Hematology</i> , 2016, 23, 371-376.	2.5	0
108	NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1067-1079.	4.9	107

#	ARTICLE	IF	CITATIONS
109	Hybrid FDG-PET/MR compared to FDG-PET/CT in adult lymphoma patients. <i>Abdominal Radiology</i> , 2016, 41, 1338-1348.	2.1	54
110	Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. <i>Blood</i> , 2016, 128, 195-203.	1.4	259
111	The Spectrum of Double Hit Lymphomas. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 1239-1249.	2.2	10
112	The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome. <i>American Journal of Hematology</i> , 2016, 91, E436-41.	4.1	44
113	Diffuse Large B-Cell Lymphoma Version 1.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 196-231.	4.9	76
114	De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort. <i>American Journal of Hematology</i> , 2016, 91, 395-399.	4.1	39
115	Extranodal Marginal Zone Lymphoma Presenting As Miliary Lung Disease. <i>Journal of Clinical Oncology</i> , 2016, 34, e27-e30.	1.6	1
116	MYC/BCL2 double-expression vs. cell-of-origin classification in diffuse large B-cell lymphoma: do we need to know both?. <i>Leukemia and Lymphoma</i> , 2016, 57, 509-511.	1.3	1
117	Burkitt Lymphoma Genome Sequencing Project (BLGSP): Introduction. <i>Blood</i> , 2016, 128, 1760-1760.	1.4	1
118	Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients. <i>Blood</i> , 2016, 128, 3243-3243.	1.4	15
119	Transcend NHL 001: Immunotherapy with the CD19-Directed CAR T-Cell Product JCAR017 Results in High Complete Response Rates in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 4192-4192.	1.4	25
120	Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303. <i>Blood</i> , 2016, 128, 469-469.	1.4	79
121	Gray Zone Lymphoma (GZL) with Features Intermediate Between Diffuse Large B-Cell Lymphoma (DLBCL) and Classical Hodgkin Lymphoma (cHL): Pathologic Classification and Clinical Outcomes from a Multicenter Consensus Study. <i>Blood</i> , 2016, 128, 4145-4145.	1.4	0
122	TP53 Immunostaining in Double-Hit and Double-Expressing High-Grade B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 1876-1876.	1.4	0
123	Routine conventional karyotyping of lymphoma staging bone marrow samples does not contribute clinically relevant information. <i>American Journal of Hematology</i> , 2015, 90, 529-533.	4.1	5
124	Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort. <i>American Journal of Hematology</i> , 2015, 90, 778-783.	4.1	71
125	Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1583-1588.	2.0	18
126	Major Cardiac Events and the Value of Echocardiographic Evaluation in Patients Receiving Anthracycline-Based Chemotherapy. <i>American Journal of Cardiology</i> , 2015, 116, 442-446.	1.6	83



#	ARTICLE	IF	CITATIONS
127	Transformative Clinical Trials in Non-Hodgkin and Hodgkin Lymphomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S141-S146.	0.4	1
128	BET Inhibitor CPI-0610 Is Well Tolerated and Induces Responses in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma: Preliminary Analysis of an Ongoing Phase 1 Study. <i>Blood</i> , 2015, 126, 1491-1491.	1.4	52
129	Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R. <i>Blood</i> , 2015, 126, 342-342.	1.4	14
130	Lenalidomide added to bendamustine-rituximab for untreated chronic lymphocytic leukemia (CLL): A phase 1 study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7082-7082.	1.6	2
131	Brentuximab vedotin plus AVD for non-bulky limited stage Hodgkin lymphoma: A phase II trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8505-8505.	1.6	11
132	Analysis of "double-hit" lymphoma cases by genetic subtype.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8543-8543.	1.6	0
133	An Adjustable Markov Model to Project Life Expectancy (LE) for Early Stage Favorable Risk Hodgkin Lymphoma Patients Treated with Contemporary Therapy. <i>Blood</i> , 2015, 126, 2635-2635.	1.4	0
134	Optimal Antiviral Prophylaxis Against Hepatitis B Reactivation in Patients Receiving Rituximab-Based Chemotherapy for Lymphoma. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2505.	7.4	9
135	Posterior Reversible Encephalopathy Syndrome (PRES) Complicating Newly-Diagnosed Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e111-e113.	0.4	6
136	Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. <i>Leukemia and Lymphoma</i> , 2014, 55, 538-543.	1.3	74
137	Addressing the Growing Cancer Burden in the Wake of the AIDS Epidemic in Botswana: The BOTSOGO Collaborative Partnership. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 468-475.	0.8	34
138	Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. <i>Blood</i> , 2014, 124, 2354-2361.	1.4	382
139	Diagnosis and Management of Castleman Disease. <i>Cancer Control</i> , 2014, 21, 266-278.	1.8	127
140	Panobinostat in Combination with Rituximab in Heavily Pretreated Diffuse Large B-Cell Lymphoma: Results of a Phase II Study. <i>Blood</i> , 2014, 124, 3055-3055.	1.4	3
141	Peripheral T-cell lymphomas (PTCL) in the modern era: Prognosis and impact of therapy in a large U.S. multicenter cohort.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19561-e19561.	1.6	0
142	Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphomas: Final Results from a Phase 1-2 Trial. <i>Blood</i> , 2014, 124, 4423-4423.	1.4	0
143	Gray Zone Lymphoma (GZL) with Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of Tumor Immunophenotype (IP) and Critical Examination of Therapy with Associated Impact on Outcome. <i>Blood</i> , 2014, 124, 1703-1703.	1.4	0
144	Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study. <i>Leukemia and Lymphoma</i> , 2013, 54, 1915-1920.	1.3	12

#	ARTICLE	IF	CITATIONS
145	Recent Advances in the Treatment of Non-Hodgkin's Lymphomas. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 671-675.	4.9	10
146	Ofatumumab As Initial Therapy For Indolent B Cell Lymphomas: A Phase II Trial. Blood, 2013, 122, 3062-3062.	1.4	14
147	A Phase III Randomized, Double Blind, Placebo Controlled Multi-Center Study Of Panobinostat For Maintenance Of Response In Patients With Hodgkin Lymphoma Who Are At Risk For Relapse After High Dose Chemotherapy and Autologous Stem Cell Transplant: Final Results After Early Trial Discontinuation. Blood, 2013, 122, 4648-4648.	1.4	10
148	Impact Of Induction Regimen and Consolidative Stem Cell Transplantation In Patients With Double Hit Lymphoma (DHL): A Large Multicenter Retrospective Analysis. Blood, 2013, 122, 640-640.	1.4	7
149	Gray Zone Lymphoma (GZL) With Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective Multicenter Analysis Of Clinical Characteristics, Treatment, Outcomes, and Prognosis In The Current Era. Blood, 2013, 122, 847-847.	1.4	2
150	HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART. Advances in Hematology, 2012, 2012, 1-8.	1.0	41
151	Unanswered Questions in HIV Hematology. Advances in Hematology, 2012, 2012, 1-2.	1.0	0
152	Double Hit Lymphomas: Evaluation of Prognostic Factors and Impact of Therapy. Blood, 2012, 120, 1619-1619.	1.4	8
153	Rituximab hypersensitivity reactions (HSR): Predictors of recurrent and severe reactions based on severity of reaction, NHL histologic subtype, and burden of disease.. Journal of Clinical Oncology, 2012, 30, e18520-e18520.	1.6	1
154	Characteristics and outcomes of extranodal NK/t-cell lymphoma (ENKL): A North American (NA) multi-institutional experience.. Journal of Clinical Oncology, 2012, 30, 8060-8060.	1.6	0
155	Survival of Newly Diagnosed T-Cell Lymphoma (TCL) in the Modern Era: Investigation of Prognostic Factors with Critical Examination of Therapy in a Multicenter US Cohort.. Blood, 2012, 120, 2728-2728.	1.4	2
156	Prognostic Factors in Patients with HIV-Associated Hodgkin Lymphoma: An Analysis of 199 Cases. Blood, 2012, 120, 1528-1528.	1.4	0
157	Kaposi's Sarcoma-Associated Herpesvirus-Related Solid Lymphoma Involving the Heart and Brain. AIDS Research and Treatment, 2011, 2011, 1-4.	0.7	10
158	Reply to intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer, 2011, 117, 2580-2581.	4.1	1
159	Primary subcutaneous <i>Alternaria alternata</i> infection of the hand in an immunocompromised host. Medical Mycology, 2011, 49, 1-5.	0.7	15
160	B Cell Lymphoma In Association with Multiple Myeloma: Analysis of the Biologic Relationship. Blood, 2011, 118, 1590-1590.	1.4	5
161	High Rate of Initial Treatment Failure in Patients with Primary Mediastinal B-Cell Lymphoma Treated with R-CHOP. Blood, 2011, 118, 1601-1601.	1.4	1
162	Everolimus in Combination with Rituximab Induces Complete Responses in Heavily Pretreated Diffuse Large B-Cell Lymphoma. Blood, 2011, 118, 1635-1635.	1.4	3

#	ARTICLE	IF	CITATIONS
163	Secondary Central Nervous System Lymphoma: A Single Center Experience. <i>Blood</i> , 2011, 118, 5181-5181.	1.4	0
164	Increased Dose Rituximab Followed by Maintenance Rituximab As Initial Therapy for Indolent B Cell Lymphomas: A Phase II Trial,. <i>Blood</i> , 2011, 118, 3716-3716.	1.4	0
165	The Clinical Course of Head and Neck Cancer in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011, 118, 4741-4741.	1.4	0
166	B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2010, 34, 327-340.	3.7	327
167	Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. <i>Cancer</i> , 2010, 116, 4283-4290.	4.1	201
168	Case 24-2010. <i>New England Journal of Medicine</i> , 2010, 363, 664-675.	27.0	12
169	Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma With Chemotherapy Without Consolidation by Radiation Therapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 1611-1615.	1.6	51
170	Primary Pancreatic Lymphoma. <i>Blood</i> , 2010, 116, 4150-4150.	1.4	4
171	Treatment Choice and Outcome In Diffuse Large B Cell Lymphoma (DLBCL) Patients 75 Years and Older. <i>Blood</i> , 2010, 116, 733-733.	1.4	1
172	AIDS-Associated Malignancies. , 2010, , 694-708.		0
173	A Phase I Dose-Escalation Trial of Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2010, 116, 1775-1775.	1.4	0
174	Breast Implant Associated Anaplastic Large Cell Lymphoma Is More Frequent and Lethal Than Previously Reported. <i>Blood</i> , 2010, 116, 4760-4760.	1.4	0
175	Risk Factors Associated with the Development of Pneumonitis After High-Dose Chemotherapy with Cyclophosphamide, BCNU, and Etoposide (CBV) Followed by Autologous Stem Cell Transplant. <i>Blood</i> , 2010, 116, 903-903.	1.4	0
176	The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas. <i>British Journal of Haematology</i> , 2009, 144, 358-366.	2.5	30
177	Case 27-2009. <i>New England Journal of Medicine</i> , 2009, 361, 900-911.	27.0	6
178	Statins May Prolong Survival in Relapsed DLBCL by Upregulating p27: a Retrospective Case-Control Study.. <i>Blood</i> , 2009, 114, 1380-1380.	1.4	1
179	Rituximab Added to CODOX-M/IVAC has No Clear Benefit Compared to CODOX-M/IVAC alone in Adult Patients with Burkitt Lymphoma.. <i>Blood</i> , 2009, 114, 1667-1667.	1.4	6
180	Statin Use Improves Overall Survival and Time to Treatment Failure in Patients with Primary CNS Lymphoma.. <i>Blood</i> , 2009, 114, 2496-2496.	1.4	2

#	ARTICLE	IF	CITATIONS
181	A Phase I Study of Lenalidomide in Combination with Fludarabine-Rituximab in Previously Untreated CLL/SLL.. Blood, 2009, 114, 3426-3426.	1.4	1
182	Rituximab Does Not Improve Progression Free (PFS) or Overall Survival (OS) in Patients with Limited Stage Diffuse Large B Cell Lymphoma (DLBCL).. Blood, 2009, 114, 3755-3755.	1.4	0
183	Case 39-2008. New England Journal of Medicine, 2008, 359, 2707-2718.	27.0	11
184	Case 8-2008. New England Journal of Medicine, 2008, 358, 1176-1187.	27.0	10
185	Early Interim FDG-PET Scan Predicts Outcome in Non-Bulky Limited Stage Hodgkin Lymphoma, but may Not Guide Use of Consolidative Radiotherapy.. Blood, 2008, 112, 1453-1453.	1.4	6
186	Rituximab Added to CODOX-M/IVAC Is Highly Effective in HIV-Negative and hiv-Positive Burkitt Lymphoma. Blood, 2008, 112, 3595-3595.	1.4	6
187	Nervous System Invasion Occurs in 4% Percent of Chronic Lymphocytic Leukemia. Blood, 2008, 112, 4200-4200.	1.4	0
188	Automated Analysis and Codification of Free Text Pathology Reports. Blood, 2008, 112, 2394-2394.	1.4	0
189	Genomic loss is our gain. Blood, 2007, 109, 6-7.	1.4	7
190	T-cell/histiocyte-rich B-cell lymphoma and the paradox of the host immune response. Leukemia and Lymphoma, 2007, 48, 1670-1671.	1.3	2
191	Intensity of FDG Uptake on PET Scan Varies by Histologic Subtype of Hodgkin Lymphoma.. Blood, 2007, 110, 4393-4393.	1.4	1
192	Intermediate Dose Intravenous Methotrexate (MTX) Dramatically Reduces the Risk of Secondary Central Nervous System (CNS) Lymphoma.. Blood, 2007, 110, 3442-3442.	1.4	1
193	T-Cell/Histiocyte-Rich B-Cell Lymphoma: Biology, Diagnosis, and Management. Oncologist, 2006, 11, 384-392.	3.7	85
194	Human Immunodeficiency Virus-Associated Malignancies. , 0, , 169-183.		0
195	HIV-Related Lymphomas. , 0, ,		0